UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                          -----------------------------

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                                 Date of Report:

                                  June 20, 2005
                        (Date of earliest event reported)

                          ----------------------------

                             GLOBAL PHARMATECH, INC.
               (Exact name of registrant as specified in charter)

                                    Delaware
         (State or other Jurisdiction of Incorporation or Organization)

             33-0976805                                     33-0976805
      (Commission File Number)                             (IRS Employer
                                                         Identification No.)

                              89 Ravine Edge Drive
                             Richmond Hill, Ontario
                                 Canada L4E 4J6
                 (Address of Principal Executive Offices and zip
                                      code)
                                  905-787-8225
              (Registrant's telephone number, including area code)

                                Autocarbon, Inc.
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17
      CFR 240.14a-12(b))

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))
<PAGE>

Item 5.02 - Departure of Directors or Principal Officers; Election of Directors,
Appointment of Principal Officers.

(b) On June 20,  2005,  Mr.  Zhongsheng  Zhang  resigned as the Chief  Financial
Officer of Global  Pharmatech,  Inc.  (the  "Company"),  effective on such date.
There were no  disagreements  between  Mr.  Zhang and the  Company on any matter
relating to the Company's operations,  policies or practices,  which resulted in
his resignation.

(c) On August 25, 2005, Junhui (Jason) Peng was appointed by the Company's Board
of  Directors  (the  "Board")  to serve as the Chief  Financial  Officer  of the
Company.

      Juunhui  (Jason)  Peng has  more  than ten  years  of  finance  management
experience in  international  companies.  From 1998 to 2004,  Mr. Peng was Chief
Financial  Officer of Germany OTTO BOCK China Inc. Mr. Peng has  experience  and
leadership in the areas of systems  planning,  analysis design and support,  and
internal control systems and budget monitoring  procedure.  From 1995 to 1998 he
was Chief Financial Offier of USA Global  Silverhawk Inc. From 1993 to 1995, Mr.
Peng was a Certified  Public  Accountant  with China  Certified  Public Inc., an
auditing and consulting company in China.

      Mr.  Peng  has  extensive   experience   and  training  in   international
environments. He has studied in Spain, Germany and Australia. Mr. Peng graduated
from  Beijing  Machinery  Industry  College in 1990 with a  Bachelors  Degree in
Accounting.  In 1999, he obtained a Master Degree in Investment from the Central
University of Finance & Banking.

      Mr. Peng has no family relationships with any of the executive officers or
directors of the Company.  There have been no  transactions to which the Company
or any of its  subsidiaries  was or is to be a party,  in which Mr.  Peng had or
will have a direct or indirect material interest.

      Pursuant to his  employment  agreement,  Mr. Peng is entitled to receive a
base salary of  RMB10,000  (US$1,205)  per month.  The  employment  agreement is
effective as of June 20, 2005 (the "Effective Date") and continues in perpetuity
unless  earlier  terminated  in  accordance  with the  terms  of the  employment
agreement. The employment agreement is filed hereto as Exhibit 10.1.
<PAGE>

Item 9.01. Financial Statements and Exhibits.

(c)      Exhibits

10.1     Employment Agreement between the Company and Juunhui (Jason) Peng.
<PAGE>

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                GLOBAL PHARMATECH, INC.


Date:  August 28, 2005          By: /s/ Xiaobo Sun
                                    --------------------------------------------
                                    Name:  Xiaobo Sun
                                    Title: President and Chief Executive Officer
{"company-data": {"conformed-name": "Global Pharmatech, Inc.", "cik": "0001157300", "assigned-sic": "2834", "irs-number": "330976805", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-67884", "film-number": "051054814"}, "business-address": {"street1": "89 RAVINE EDGE DRIVE", "street2": "RICHMOND HILL", "city": "ONTARIO", "state": "A6", "zip": "L4E 4J6", "phone": "905-787-8225"}, "mail-address": {"street1": "89 RAVINE EDGE DRIVE", "street2": "RICHMOND HILL", "city": "ONTARIO", "state": "A6", "zip": "L4E 4J6"}, "former-company": [{"former-conformed-name": "AUTOCARBON INC", "date-changed": "20021118"}, {"former-conformed-name": "AUTOCARBON COM INC", "date-changed": "20020501"}, {"former-conformed-name": "AUTO CARBON COM INC", "date-changed": "20010810"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                          -----------------------------

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report:

                                  June 20, 2005
                        (Date of earliest event reported)

                          ----------------------------

                             GLOBAL PHARMATECH, INC.
               (Exact name of registrant as specified in charter)

                                    Delaware
         (State or other Jurisdiction of Incorporation or Organization)

             33-0976805                                     33-0976805
      (Commission File Number)                             (IRS Employer
                                                         Identification No.)

                              89 Ravine Edge Drive
                             Richmond Hill, Ontario
                                 Canada L4E 4J6
                 (Address of Principal Executive Offices and zip
                                      code)
                                  905-787-8225
              (Registrant's telephone number, including area code)

                                Autocarbon, Inc.
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17
      CFR 240.14a-12(b))

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))
Item 5.02 - Departure of Directors or Principal Officers; Election of Directors,
Appointment of Principal Officers.

(b) On June 20,  2005,  Mr.  Zhongsheng  Zhang  resigned as the Chief  Financial
Officer of Global  Pharmatech,  Inc.  (the  "Company"),  effective on such date.
There were no  disagreements  between  Mr.  Zhang and the  Company on any matter
relating to the Company's operations,  policies or practices,  which resulted in
his resignation.

(c) On August 25, 2005, Junhui (Jason) Peng was appointed by the Company's Board
of  Directors  (the  "Board")  to serve as the Chief  Financial  Officer  of the
Company.

      Juunhui  (Jason)  Peng has  more  than ten  years  of  finance  management
experience in  international  companies.  From 1998 to 2004,  Mr. Peng was Chief
Financial  Officer of Germany OTTO BOCK China Inc. Mr. Peng has  experience  and
leadership in the areas of systems  planning,  analysis design and support,  and
internal control systems and budget monitoring  procedure.  From 1995 to 1998 he
was Chief Financial Offier of USA Global  Silverhawk Inc. From 1993 to 1995, Mr.
Peng was a Certified  Public  Accountant  with China  Certified  Public Inc., an
auditing and consulting company in China.

      Mr.  Peng  has  extensive   experience   and  training  in   international
environments. He has studied in Spain, Germany and Australia. Mr. Peng graduated
from  Beijing  Machinery  Industry  College in 1990 with a  Bachelors  Degree in
Accounting.  In 1999, he obtained a Master Degree in Investment from the Central
University of Finance & Banking.

      Mr. Peng has no family relationships with any of the executive officers or
directors of the Company.  There have been no  transactions to which the Company
or any of its  subsidiaries  was or is to be a party,  in which Mr.  Peng had or
will have a direct or indirect material interest.

      Pursuant to his  employment  agreement,  Mr. Peng is entitled to receive a
base salary of  RMB10,000  (US$1,205)  per month.  The  employment  agreement is
effective as of June 20, 2005 (the "Effective Date") and continues in perpetuity
unless  earlier  terminated  in  accordance  with the  terms  of the  employment
agreement. The employment agreement is filed hereto as Exhibit 10.1.
Item 9.01. Financial Statements and Exhibits.

(c)      Exhibits

10.1     Employment Agreement between the Company and Juunhui (Jason) Peng.
SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                GLOBAL PHARMATECH, INC.

Date:  August 28, 2005          By: /s/ Xiaobo Sun
                                    --------------------------------------------
                                    Name:  Xiaobo Sun
                                    Title: President and Chief Executive Officer